IS PHARMACOLOGY DIFFICULT®️ Podcast
Welcome all to "Is Pharmacology Difficult®️ podcast ". This is a Pharmacology podcast !! I am your host, Dr Radhika Vijay, M.B.B.S., M.D. Pharmacology, Sardar Patel Medical College, Bikaner, Rajasthan, India. Pharmacology (medical sciences) is my subject and I think Communicating about it to the masses is very essential. It is of great value and importance to every layman. The episodes here will be in simple English language (with few phrases and add ons of my favourite french language). The basic motto is to create an awareness and impart knowledge of the subject to all interested, concerned, curious and visitors. Pharmacology, the "SCIENCE OF DRUGS", which hold an important place in everyone's life. Here, I will discuss basic tips, strategies and ideas to study medical pharmacology easily and effectively especially for medical, nursing, dental and pharmacy schools and students. Even if you are not from Science stream, this information would be beneficial to you and therefore pay some valuable minutes to this Pharmacology Podcast, and you will not be in loss !! The descriptions will be short pieces of science work lengthy enough to engage you and not to test your patience! So, go ahead, lend your ears to these crispy informative audio files and empower and enrich your sea of knowledge and let me know "IS PHARMACOLOGY DIFFICULT?" For various links, please visit: https://linktr.ee/ispharmacologydifficult. Disclaimer: All the content of the podcast audio is expressed in my own language and learning and understanding viewpoints. References are from the best and reputed subject (Pharmacology) text books, blogs, journals and drug information from reputed and best online sources. I make best efforts to convey the most accurate and updated information of the subject of medical sciences in my special way. I take no money from pharmaceutical industry or drug companies for my podcast. You are most welcome to post your comments, suggestions, etc. through "Contact" page on my website: www.ispharmacologydifficult.com. You all are well known that medical sciences subjects are ever changing, updated and ever evolving, hence no guarantee is taken if the information conveyed in this podcast turns outdated or obsolete with changing and evolving times. This podcast is an expression of my learnings and experiences and in no way representative of any standard authority. Privacy Notice: I collect only email addresses of the subscribers and in no circumstances they will be shared or displayed anywhere on podcast/website/newsletter. Copyright & Distribution: All the contents of "IS PHARMACOLOGY DIFFICULT®️" podcast/website/blog/newsletter are copyrighted. Though all the content related to podcast and various social media handles is free! "BUT" in no way or under no circumstances shall- Any of the podcast content/show notes/blog post/newsletter content/youtube video artwork/podcast artwork and ideas should be used or reproduced or distributed.
IS PHARMACOLOGY DIFFICULT®️ Podcast
Is Pharmacology Difficult Podcast- World Hypertension Day
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
Would love to know your opinions & expectations -Dr Radhika Vijay
Welcome all to IS PHARMACOLOGY DIFFICULT Podcast! I am Dr Radhika Vijay
Today is World Hypertension Day
In this episode, I will talk about latest medications for hypertension
The Podcast is for all- doctor, pharmacologist, med student, pharmacist and laymen interested in science of Pharmacology, drugs and medicines
My podcast is featured in "TOP 20 PHARMACOLOGY PODCASTS"- Check the link here:
https://podcast.feedspot.com/pharmacology_podcasts/
My podcast is featured in " 40 BEST INDIA EDUCATION PODCASTS"- Check the link here:
https://podcast.feedspot.com/india_education_podcasts/
My podcast is featured in "BEST SCIENCE PODCASTS"- Check the link here:
https://podcasts.feedspot.com/india_science_podcasts/
My podcast is featured in "BEST INDIAN MEDICAL PODCASTS". Check the link here:
https://podcasts.feedspot.com/india_medical_podcasts/?feedid=5503395
For all the updates and latest episodes of my podcast, please visit www.ispharmacologydifficult.com where you can also sign up for a free monthly newsletter of mine.
"Pharmacology Further" E-Newsletter and Podcast:
The links for these are at all my websites and specifically:
Link for E-Newsletter: https://pharmacologyfurther.substack.com/
Link for the E-Newsletter Podcast: https://www.pharmacologyfurther.com
It actually contains lot of updates about the medical sciences, drug information and my podcast updates also.
You can follow me on different social media handles like twitter, insta, facebook and linkedin. They all are with same name "IS PHARMACOLOGY DIFFICULT".
If you are listening for the first time, do follow me here, whatever platform you are consuming this episode, stay tuned, do rate and review on ITunes, Apple podcasts, stay safe, stay happy, stay enlightened, Thank you!!
Hello everyone, welcome back to my podcast. Welcome back to my channel, it's Pharmacology Difficult Podcast. And wishing everybody a very wonderful awareness full of World Hypertension Day. And today is 17th of May 2026. So, how we can increase our awareness and celebrate the day that is the important day of today, World Hypertension Day. So I have got for you the newest breakthrough blood pressure medications and a brief overview of each one of that. So, first of all, let's talk about the newest recent additions to the hypertension treatment. The first one is Backstrostat. So it's a novel eldesteron synthase inhibitor that disrupts the production of aldosterone before it can cause salt retention and high blood pressure. It's an investigational drug, first in class, very highly selective drug, and it lowers the blood pressure by reducing the production of aldosterone, a hormone that causes the body to retain salt and water without interfering with the cortisol production. And medical condition it can be used in is for resistant hypertension. It targets the treatment resistant or uncontrolled hypertension who are already taking more blood pressure medications without success. In such patients, it targets the resistant hypertension than primary eldosteronism. It can cure that also. It is also in clinical development for treating this excess aldosterone production. And it is in phase 3 success, and the target reaches approximately 40% of the trial patients. They have achieved a systolic blood pressure reading below 120-130 millimeter AG. And unlike some other mineralocorticoid receptor antagonist, it is a very highly selective drug. It spares the CYP11B1 enzyme and inhibits only the CYP11B2 enzyme, which makes aldosterone. So it is not affecting the cortisol production, it is only affecting the aldosterone production. This helps avoid many of the hormonal side effects associated with older therapies. Its side effects is a very well-tolerated drug, and clinical trials have noted mild to moderate adverse effects, occasionally some elevated potassium levels like hyperkalemia. And when there is a discontinuation of the drug temporarily, then this hyperkalemia, which is caused, it can actually resolve. Second important drug that I want to talk about is aprocitentin. And it's an endothelin-1 receptor antagonist. It is a first of its kind drug with a completely novel mechanism for treating resistant hypertension. It blocks the endothellin receptors that causes the blood vessels to constrict, widening them and actively lowering the blood pressure. Next important drug: Laurindrostat. It is similar to Paxtrostat. It inhibits the biosynthesis of eldosterone. It is also in early phase trials. While amongst these drugs, Aprocitentin is an FDA-approved drug. It is approved in March 2024. It's a first new class of oral antihypertensive medication indicates. Then another recent advancement in blood pressure medication, it focuses uh as an experimental long-acting injection administered every three to six months that inhibits angiotensin production. Angiotensin, you all know, is a chemical that constricts the blood vessels and raises the blood pressure. So zilla bisiran. Zillabiciran, it acts as a long-acting injection. I want to talk a little bit more about zillabiciran. Zillabiciran is an investigational RNA interference therapeutic under the development for the treatment of hypertension. RNA interference, that is RNA small I, that is the abbreviation. It uses small interfering RNA, SIRNA, to target and degrade the messenger RNA, mRNA, that codes for angiotensinogen. By blocking the production of angiotensinogen, it prevents the formation of downstream hormones like angiotensin 2, which causes blood vessels to constrict, finally raising the blood pressure. And it is phase 1 and phase 2 clinical trials have shown quite good efficacy, meaningful results. It is currently advancing through the phase 3 clinical programs. Clinical trials have indicated favourite safety profile, with most common and mild side effects being temporary pain errythma at the injection site, which are very common side effects, not a permanent one. Renal and hepatic safety. The drug does not cause major renal, hepatic, or electrolyte disturbances. And because it is still in clinical testing, it has not been approved for use for evaluated for safety and efficacy by FDA yet. So this is how we have celebrated today, World Hypertension Day. Hope you like this information about the wonderful drugs and hope you found it useful. If you did, don't forget to like and subscribe my channel. Till the next time. Thank you. Take care. Bye bye. Mamia.
Podcasts we love
Check out these other fine podcasts recommended by us, not an algorithm.
Pharmacology Further Podcast
*Pharmacology | Books & Writing | Nutrition*